Skip to main content
Top
Published in: Globalization and Health 1/2019

Open Access 01-12-2019 | Public Health | Review

USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health

Authors: Ronald Labonté, Eric Crosbie, Deborah Gleeson, Courtney McNamara

Published in: Globalization and Health | Issue 1/2019

Login to get access

Abstract

Background

In late 2018 the United States, Canada, and Mexico signed a new trade agreement (most commonly referred to by its US-centric acronym, the United States-Mexico-Canada Agreement, or USMCA) to replace the 1994 North American Free Trade Agreement (NAFTA). The new agreement is the first major trade treaty negotiated under the shadow of the Trump Administration’s unilateral imposition of tariffs to pressure other countries to accept provisions more favourable to protectionist US economic interests. Although not yet ratified, the agreement is widely seen as indicative of how the US will engage in future international trade negotiations.

Methods

Drawing from methods used in earlier health impact assessments of the Trans-Pacific Partnership agreement, we undertook a detailed analysis of USMCA chapters that have direct or indirect implications for health. We began with an initial reading of the entire agreement, followed by multiple line-by-line readings of key chapters. Secondary sources and inter-rater (comparative) analyses by the four authors were used to ensure rigour in our assessments.

Results

The USMCA expands intellectual property rights and regulatory constraints that will lead to increased drug costs, particularly in Canada and Mexico. It opens up markets in both Canada and Mexico for US food exports without reducing the subsidies the US provides to its own producers, and introduces a number of new regulatory reforms that weaken public health oversight of food safety. It reduces regulatory policy space through new provisions on ‘technical barriers to trade’ and requirements for greater regulatory coherence and harmonization across the three countries. It puts some limitations on contentious investor-state dispute provisions between the US and Mexico, provisions often used to challenge or chill health and environmental measures, and eliminates them completely in disputes between the US and Canada; but it allows for new ‘legacy claims’ for 3 years after the agreement enters into force. Its labour and environmental chapters contain a few improvements but overall do little to ensure either workers’ rights or environmental protection.

Conclusion

Rather than enhancing public health protection the USMCA places new, extended, and enforceable obligations on public regulators that increase the power (voice) of corporate (investor) interests during the development of new regulations. It is not a health-enhancing template for future trade agreements that governments should emulate.
Footnotes
1
TRIPS-Plus refers to intellectual property rights which extend beyond those provided for by the WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
 
2
Like data protection, ‘market protection’ applies to the clinical trial data submitted to regulators and commences from the date of marketing approval for the originator product. However, market protection differs from data protection in that the regulator can accept and evaluate an application for a follow-on product during the period of market protection (although marketing approval can’t be granted until the market protection period expires).
 
3
It is not possible to make identical generic copies of biologics due to their complexity, but biosimilars, which are highly similar to the original biologic and have the same therapeutic effect, can often be made at a lower cost than the original biologic.
 
4
The USMCA chapter on Good Regulatory Practice further requires Parties, in an annual retrospective review of their regulations and at the instigation of any “interested person” from any other Party, to “consider…common approaches to the display of product or consumer information”, another potential way for the US to initiate a challenge to Canadian or Mexican front-of-pack interpretative nutritional labeling.
 
5
A US corporation sued a provincial government after an environmental impact assessment rules against its massive quarry and marine shipping terminal, in part because it was contrary to community values. Despite the investor winning the suit, the panel, noting the quarry was unlikely ever to go ahead, denied the US$477 million investor claim for 50 years of lost profit and awarded only US$17 million for lost opportunity costs [38].
 
6
As with other new FTAs, such as the CPTPP, the USMCA has been promoted for the positive impact it will have on economic growth and employment creation. But there is also the question of who benefits from such an agreement. To date there have been two econometric studies attempting to estimate economic and employment gains arising from the USMCA, both focusing on the US. In April 2019 the US International Trade Commission (USITC) released a lengthy study in which it forecast gains of US$68.2 billion and 176,000 new jobs [42]. However, these simulated gains rest on several assumptions, including only slight restrictions on the ability of dislocated workers to move to other employment, and an attempt to model “reduced policy uncertainty”, a novel approach not embraced by many other economists. Remove the “reduced policy uncertainty” assumption and the US economy declines slightly, losing US$22.6 billion in value and almost 60,000 jobs. The second study, published one month earlier by the IMF and using similar econometric modelling to the USITC report but without the “reduced policy uncertainty” assumption, concluded that, at most and across all three countries, the USMCA would generate an additional US$540 million in aggregate GDP [55]. Canada and Mexico both gain while the US loses, but the amounts are so low that “the effects on members’ real GDP is negligible” (p.12). However, if the US steel and aluminum tariffs and Canadian and Mexican retaliatory taxes are all removed, the USMCA could generate an additional $US2.5 billion in aggregate welfare, most of it going to the US.
 
7
Other measures of the USMCA can also have negative environmental and subsequent health impacts. As with continuing ISDS provisions between the US and Mexico with respect to fracking and oil drilling, a side letter agreement between Canada and the US guarantees either country access to their pipelines for purposes of importation. This could increase oil and natural gas transmissions with subsequent risk of fugitive leaks and emissions, posing both environmental and human health risks.
 
8
The WTO Appellate Body (AB) is comprised of seven ‘judges’ appointed for a fixed term, and has the power to uphold, modify, or reverse a dispute panel decision. At least three members of the AB must render a final decision for any action on a dispute to be binding. The US considers the AB to be exercising ‘judicial activism’ particularly regarding disputes over anti-dumping measures, which the US has raised with regard to both China and the EU, and generally loses on appeal to the Appellate Body. The US has a particular concern over how China’s system of ‘state capitalism’ threatens its model of liberalized international trade, which it believes is the foundation of the WTO. With the US blocking new appointments to the AB, however, the WTO dispute settlement process could break down and with it, the entire multilateral trading system creating what some trade analysts characterize as a ‘return to the wild west of trade’ [60].
 
Literature
3.
4.
go back to reference Labonté R, Schram A, Ruckert A. The trans-Pacific partnership agreement and health: few gains, some losses, many risks. Glob Health. 2016;12(1):25–32.CrossRef Labonté R, Schram A, Ruckert A. The trans-Pacific partnership agreement and health: few gains, some losses, many risks. Glob Health. 2016;12(1):25–32.CrossRef
5.
go back to reference Ruckert A, Schram A, Labonté R, Friel S, Gleeson D, Thow AM. Policy coherence, health and the sustainable development goals: a health impact assessment of the trans-Pacific partnership. Crit Public Health. 2016;27(1):86–96.CrossRef Ruckert A, Schram A, Labonté R, Friel S, Gleeson D, Thow AM. Policy coherence, health and the sustainable development goals: a health impact assessment of the trans-Pacific partnership. Crit Public Health. 2016;27(1):86–96.CrossRef
6.
go back to reference Hirono K, Haigh F, Gleeson D, Harris P, Thow AM, Friel S. Is health impact assessment useful in the context of trade negotiations? A case study of the trans Pacific partnership agreement. BMJ Open. 2016;6(4):e010339.PubMedPubMedCentralCrossRef Hirono K, Haigh F, Gleeson D, Harris P, Thow AM, Friel S. Is health impact assessment useful in the context of trade negotiations? A case study of the trans Pacific partnership agreement. BMJ Open. 2016;6(4):e010339.PubMedPubMedCentralCrossRef
9.
go back to reference Lexchin J, Gleeson D. The trans Pacific partnership agreement and pharmaceutical regulation in Canada and Australia. Int J Health Serv Plan Adm Eval. 2016;46(4):597–613.10.PubMedCrossRef Lexchin J, Gleeson D. The trans Pacific partnership agreement and pharmaceutical regulation in Canada and Australia. Int J Health Serv Plan Adm Eval. 2016;46(4):597–613.10.PubMedCrossRef
10.
go back to reference Lopert R, Gleeson D. The high price of “free” trade: U.S. trade agreements and access to medicines. J Law Med Ethics J Am Soc Law Med Ethics. 2013;41(1):199–223. Lopert R, Gleeson D. The high price of “free” trade: U.S. trade agreements and access to medicines. J Law Med Ethics J Am Soc Law Med Ethics. 2013;41(1):199–223.
12.
go back to reference Sell SK. Private Power, Public Law: The Globalization of Intellectual Property Rights [Internet]. Cambridge, United Kingdom: Cambridge University Press; 2003. p. 244. Sell SK. Private Power, Public Law: The Globalization of Intellectual Property Rights [Internet]. Cambridge, United Kingdom: Cambridge University Press; 2003. p. 244.
13.
go back to reference Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha declaration: a database analysis. PLoS Med. 2012;9(1):1–9.CrossRef Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha declaration: a database analysis. PLoS Med. 2012;9(1):1–9.CrossRef
14.
go back to reference t’ Hoen EF, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the agreement on trade-related aspects of intellectual property rights, 2001–2016. Bull World Health Organ. 2018;96:185–93.CrossRef t’ Hoen EF, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the agreement on trade-related aspects of intellectual property rights, 2001–2016. Bull World Health Organ. 2018;96:185–93.CrossRef
18.
go back to reference Koivusalo M, Schrecker T, Labonté R. Globalization and policy space for health and social determinants of health. In: Globalization and health: pathways, evidence and policy. United Kingdom: Routledge; 2009. p. 105–30. Koivusalo M, Schrecker T, Labonté R. Globalization and policy space for health and social determinants of health. In: Globalization and health: pathways, evidence and policy. United Kingdom: Routledge; 2009. p. 105–30.
28.
go back to reference Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015 Jun;101(6):1144–54.PubMedPubMedCentralCrossRef Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015 Jun;101(6):1144–54.PubMedPubMedCentralCrossRef
29.
go back to reference Goran MI, Ulijaszek SJ, Ventura EE. High fructose corn syrup and diabetes prevalence: a global perspective. Glob Public Health. 2013;8(1):55–64.PubMedCrossRef Goran MI, Ulijaszek SJ, Ventura EE. High fructose corn syrup and diabetes prevalence: a global perspective. Glob Public Health. 2013;8(1):55–64.PubMedCrossRef
30.
go back to reference Barlow P, McKee M, Basu S, Stuckler D. Impact of the north American free trade agreement on high-fructose corn syrup supply in Canada: a natural experiment using synthetic control methods. Can Med Assoc J. 2017;189(26):E881–7.CrossRef Barlow P, McKee M, Basu S, Stuckler D. Impact of the north American free trade agreement on high-fructose corn syrup supply in Canada: a natural experiment using synthetic control methods. Can Med Assoc J. 2017;189(26):E881–7.CrossRef
33.
go back to reference Thow AM, Jones A, Hawkes C, Ali I, Labonté R. Nutrition labelling is a trade policy issue: lessons from an analysis of specific trade concerns at the World Trade Organization. Health Promot Int. 2018;33(4):561–71.PubMed Thow AM, Jones A, Hawkes C, Ali I, Labonté R. Nutrition labelling is a trade policy issue: lessons from an analysis of specific trade concerns at the World Trade Organization. Health Promot Int. 2018;33(4):561–71.PubMed
36.
go back to reference Liu S, Hammond SK, Rojas-Cheatham A. Concentrations and potential health risks of metals in lip products. Environ Health Perspect. 2013 Jun;121(6):705–10.PubMedPubMedCentralCrossRef Liu S, Hammond SK, Rojas-Cheatham A. Concentrations and potential health risks of metals in lip products. Environ Health Perspect. 2013 Jun;121(6):705–10.PubMedPubMedCentralCrossRef
39.
go back to reference Lin C-F, Liu H-W. Regulatory rationalisation clauses in FTAs: a complete survey of the US, EU and China. Melb J Int Law. 2018;19(1):149–68. Lin C-F, Liu H-W. Regulatory rationalisation clauses in FTAs: a complete survey of the US, EU and China. Melb J Int Law. 2018;19(1):149–68.
45.
go back to reference McNamara C, Labonté R. Trade, labour markets and health: a prospective policy analysis of the trans-Pacific partnership. Int J Health Serv. 2016;47(2):277–97.PubMedCrossRef McNamara C, Labonté R. Trade, labour markets and health: a prospective policy analysis of the trans-Pacific partnership. Int J Health Serv. 2016;47(2):277–97.PubMedCrossRef
46.
go back to reference McNamara C. Trade liberalization, social policies and health: an empirical case study. Glob Health. 2015;11(1):42–61.CrossRef McNamara C. Trade liberalization, social policies and health: an empirical case study. Glob Health. 2015;11(1):42–61.CrossRef
Metadata
Title
USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health
Authors
Ronald Labonté
Eric Crosbie
Deborah Gleeson
Courtney McNamara
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Public Health
Published in
Globalization and Health / Issue 1/2019
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-019-0476-8

Other articles of this Issue 1/2019

Globalization and Health 1/2019 Go to the issue